Medical News Today: Signs and symptoms of MS in women
Multiple sclerosis (MS) is a disease that damages the nerves and causes a wide range of symptoms, including vision problems and numbness. In this article, learn about the symptoms of MS in women.
Authors: Sakurai K, Shinohara K, Imai T, Yamano Y, Hasegawa Y Abstract This case concerned a 39-year-old woman diagnosed with uterine fibroids. Upon initiation of gonadotropin-releasing hormone (GnRH) agonist therapy, she experienced various neurological deficits but did not seek medical attention because of gradual spontaneous symptom improvement. Upon completing four courses of GnRH agonist therapy, she began experiencing severe neurological symptoms and was diagnosed with multiple sclerosis (MS). Although her symptoms improved with steroid pulse therapy, serious sequelae remained. GnRH agonist therapy can exacer...
Publication date: Available online 13 August 2020Source: Autoimmunity ReviewsAuthor(s): Mahsa Ghajarzadeh, Aida Mohammadi, Mohammad Ali Sahraian
Publication date: Available online 13 August 2020Source: Autoimmunity ReviewsAuthor(s): Tobias Moser, Katja Akgün, Undine Proschmann, Johann Sellner, Tjalf Ziemssen
Conclusions: We found an association between the rs10735781 and rs6897932 polymorphisms on the EVI5 and IL7RA genes, respectively, with increased MS in the Iranian population. Therefore, single nucleotide polymorphisms in the EVI5 and IL7RA genes can be considered a prognostic marker of MS. PMID: 32760600 [PubMed]
ConclusionThe present patient suffered from a probable “autoimmune depression” in the context of newly diagnosed multiple sclerosis with typical MRI and CSF pathologies, alongside mild concomitant latent systemic autoimmune process (with high-titer ANAs and lymphopenia) and unknown antineuronal antibodies. The case report illustrates that a depressive syndrome suggestive of primary idiopathic depressive disorder may be associated with an autoimmune brain involvement. The detection of such organic affective disorders is of high clinical relevance for affected patients, as it enables alternative and more causal treatment approaches.
Authors: Pantazou V, Pot C, Du Pasquier R, Le Goff G, Théaudin M Abstract BACKGROUND: The current treated MS population is very different from that of patients in randomized clinical trials. OBJECTIVES: To study the long-term efficacy and tolerance of fingolimod (FTY) and dimethyl fumarate (DMF), both available as first-line treatment in early-treated treatment-naïve MS patients. METHODS: Retrospective analysis of 75 patients from our prospective MS registry fulfilling the inclusion criteria: FTY or DMF as first-line treatment, treatment initiation within 36months of disease onset and treatment ...
Publication date: October 2020Source: Multiple Sclerosis and Related Disorders, Volume 45Author(s): Mohammad Sarmadi, Zeinab Bidel, Fereshteh Najafi, Rema Ramakrishnan, Farshad Teymoori, Hassan Azhdari Zarmehri, Milad Nazarzadeh
Authors: Pyka-Fosciak G, Lis GJ, Litwin JA Abstract Matrix metalloproteinases (MMPs) regulated by their tissue inhibitors (TIMPs) play a significant role in the pathogenesis of multiple sclerosis (MS) and its mouse model, experimental autoimmune encephalomyelitis (EAE), as they degrade extracellular matrix including vascular basal laminae and by damaging blood-brain barrier (BBB) facilitate transmigration of immune cells into the central nervous system. MMPs are also involved in destruction of myelin sheaths, leading to axonal and neuronal loss. The aim of the present study was to assess whether natalizumab, a tran...
Conclusion: Secondary trigeminal neuralgia may be explained by a pathological process in vicinity of the spinal trigeminal nuclei. Removing the tumor may be expected to provide complete and lasting pain relief. PMID: 32754348 [PubMed]
Conclusion: CNS neoplasms including meningioma should be considered in MS patients presenting with newly onset neurological symptoms not entirely consistent with demyelinating disease. Both disease processes should be addressed with appropriate long-term follow-up. PMID: 32754367 [PubMed]